Johnson & Johnson - June 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Johnson & Johnson: Key facts and statistics - LTM June 2024

A summary company profile, detailing Johnson & Johnson’s business operations and financial highlights.

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Johnson & Johnson - March 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Regenerative Healthcare - Stem Cells & ALS Thematic 10062024

Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...

Moody's Ratings assigns Aaa ratings to Johnson & Johnson's sr. notes; ...

Moody's Ratings (Moody's) assigned Aaa ratings to the new USD and EUR denominated senior unsecured note offerings of Johnson & Johnson ("J&J"). There are no changes to J&J's existing ratings including the Aaa senior unsecured long-term rating or the Prime-1 short-term rating. The outlook remains unc...

Johnson & Johnson: Update following ratings affirmation

Our credit view of this issuer reflects its strong global scale and diversity and conservative financial policies, offset by unresolved talc litigation exposures.

Shockwave Being Bought by Johnson & Johnson for $335

Moody's Ratings affirms J&J's Aaa ratings; stable outlook

Moody's Ratings (Moody's) affirmed the ratings of Johnson & Johnson ("J&J") including the Aaa long-term issuer rating, Aaa senior unsecured rating, (P)Aaa senior unsecured medium term note program rating and Prime-1 commercial paper rating. The outlook remains stable. This rating action follows th...

Johnson & Johnson - December 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Johnson & Johnson: 1 director

A director at Johnson & Johnson sold 8,891 shares at 162.160USD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

Saponia dd - Company Profile and SWOT Analysis

Summary Saponia dd - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Saponia dd (Saponia) is a manufacturer of home care and personal hygiene products. The company’s product portfolio comprises dish detergents, laundry detergents, toothbrushes, baby care, hand cream, shaving ...

Johnson & Johnson - October 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Johnson & Johnson: Solid operating performance and pipeline execution,...

Our credit view of this issuer reflects its strong scale, diversity, profit margins and cash flow, offset by unresolved legal exposures and event risk associated with acquisitions.

Johnson & Johnson - July 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's: New setback in J&J talc litigation raises uncertainty

Moody's Investors Service commented that the recent setback in Johnson & Johnson's (Aaa stable) efforts to resolve outstanding talc litigation is credit negative. A federal judge dismissed the bankruptcy filing by J&J's subsidiary LTL Management LLC (LTL). This process would significantly reduce the...

Johnson & Johnson: New setback in talc litigation raises uncertainty

J&J is appealing the dismissal of the LTL bankruptcy filing, but is prepared to continue working with talc plaintiffs or otherwise return to the tort system, raising uncertainty

Johnson & Johnson - April 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

JOHNSON & JOHNSON Flash Note

Johnson & Johnson is a diversified healthcare products company. The Company is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer Health, Pharmaceutical and MedTech. Its primary focus is products related to human health and well-being.